Study details
Enrolling now
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety
University of Cincinnati
NCT IDNCT04623099ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
132
Study length
about 5.7 years
Ages
12–17
Locations
1 site in OH
About this study
Researchers are testing whether a personalized approach to escitalopram dosing improves anxiety treatment in children. Participants will be randomly assigned to either standard or pharmacogenetically-guided escitalopram, based on their genetic makeup. The trial will last 2094 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Escitalopram
PhasePhase 4
DrugEscitalopram
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
escitalopram (SSRI; increases serotonin availability)
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Tolerability-Activation
Body systems
Psychiatry / Mental Health